Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.

ABSTRACT:

Background

Patients with type 2 diabetes have a 40% increased risk of bladder cancer. Thiazolidinediones, especially pioglitazone, may increase the risk. We conducted a systematic review and meta-analysis to evaluate the risk of bladder cancer among adults with type 2 diabetes taking thiazolidinediones.

Methods

We searched key biomedical databases (including MEDLINE, Embase and Scopus) and sources of grey literature from inception through March 2012 for published and unpublished studies, without language restrictions. We included randomized controlled trials (RCTs), cohort studies and case-control studies that reported incident bladder cancer among people with type 2 diabetes who ever (v. never) were exposed to pioglitazone (main outcome), rosiglitazone or any thiazolidinedi

SUBMITTER: Colmers IN 

PROVIDER: S-EPMC3447078 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature